Cold‐inducible RNA‐binding protein promotes the development of liver cancer
Most hepatocellular carcinomas (HCCs) develop in the context of chronic liver inflammation. Oxidative stress is thought to play a major role in the pathogenesis of HCC development. In this study, we examined whether cold‐inducible RNA‐binding protein (Cirp) controls reactive oxygen species (ROS) acc...
Saved in:
Published in | Cancer science Vol. 106; no. 4; pp. 352 - 358 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
John Wiley & Sons, Inc
01.04.2015
BlackWell Publishing Ltd |
Subjects | |
Online Access | Get full text |
ISSN | 1347-9032 1349-7006 1349-7006 |
DOI | 10.1111/cas.12611 |
Cover
Summary: | Most hepatocellular carcinomas (HCCs) develop in the context of chronic liver inflammation. Oxidative stress is thought to play a major role in the pathogenesis of HCC development. In this study, we examined whether cold‐inducible RNA‐binding protein (Cirp) controls reactive oxygen species (ROS) accumulation and development of HCC by using murine models of hepatocarcinogenesis and human liver samples. Cirp expression, ROS accumulation, and CD133 expression were increased in the liver of tumor‐harboring mice. Cirp deficiency reduced production of interleukin‐1β and interleukin‐6 in Kupffer cells, ROS accumulation, and CD133 expression, leading to attenuated hepatocarcinogenesis. Thioacetamide treatment enhanced hepatic expression of CD133 and phosphorylated signal transducer and activator of transcription 3 (STAT3), which was prevented by treatment with the antioxidant butylated hydroxyanisole. Intriguingly, the risk of human HCC recurrence is positively correlated with Cirp expression in liver. Cirp appears to play a critical carcinogenic function and its expression might be a useful biomarker for HCC risk prediction.
Cirp would enhance tumorigenesis by controlling ROS accumulation. Cirp might be associated with stem cell maintenance. Cirp expression might be a useful biomarker for HCC risk prediction. |
---|---|
Bibliography: | Yasuda Medical Foundation; Takeda Science Foundation; Japan Foundation for Research and Promotion of Endoscopy; Japan Society for the Promotion of Science. Funding Information ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Funding Information Yasuda Medical Foundation; Takeda Science Foundation; Japan Foundation for Research and Promotion of Endoscopy; Japan Society for the Promotion of Science. |
ISSN: | 1347-9032 1349-7006 1349-7006 |
DOI: | 10.1111/cas.12611 |